What does Braveheart Bio, Inc. do?
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of…
What is Braveheart Bio, Inc.'s P/E and P/B ratio?
Braveheart Bio, Inc. has a P/E ratio of -3.5 and a P/B ratio of -20.17.
What is Braveheart Bio, Inc.'s debt-to-equity ratio?
Braveheart Bio, Inc. has a debt-to-equity ratio of 0.00.
How much does Braveheart Bio, Inc. owe compared with what it owns?
Braveheart Bio, Inc. owes $1.76 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Braveheart Bio, Inc.'s Positivity rank?
Braveheart Bio, Inc. is ranked #6,588 of 6,774 companies globally and #3,830 of 4,000 in United States on PositoAI, with a Positivity Score of -27,121.
Does Braveheart Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Braveheart Bio, Inc..
Where can I read the latest news about Braveheart Bio, Inc.?
Recent headlines about Braveheart Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Braveheart Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Braveheart Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.